Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02852239 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02852239 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 22 participants.
The verdict
NCT02852239, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
To characterize the pharmacokinetics and safety of dabrafenib following a single 100 mg oral dose in subjects with severe renal impairment and end stage renal disease not on dialysis.
Interventions
- DRUG dabrafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-12-19 |
| Est. Completion | 2019-09-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02852239
The ClinicalTrials.gov registry entry for NCT02852239 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dabrafenib is the first listed.
NCT02852239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02852239 about?
NCT02852239 is a clinical study titled "Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment". To characterize the pharmacokinetics and safety of dabrafenib following a single 100 mg oral dose in subjects with severe renal impairment and end stage renal disease not on dialysis.
What is the current status of trial NCT02852239?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2016-12-19. Estimated completion is 2019-09-27.
What interventions are being tested in trial NCT02852239?
The interventions under investigation include: dabrafenib (DRUG).
Who is sponsoring clinical trial NCT02852239?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.